BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29912938)

  • 1. Treatment patterns and steroid dose for adult minimal change disease relapses: A retrospective cohort study.
    Ozeki T; Ando M; Yamaguchi M; Katsuno T; Kato S; Yasuda Y; Tsuboi N; Maruyama S
    PLoS One; 2018; 13(6):e0199228. PubMed ID: 29912938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome.
    Eguchi A; Takei T; Yoshida T; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2010 Jan; 25(1):124-9. PubMed ID: 19740915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial.
    Shirai S; Imai N; Sueki S; Matsui K; Tominaga N; Sakurada T; Yasuda T; Kimura K; Shibagaki Y
    Clin Exp Nephrol; 2018 Apr; 22(2):283-290. PubMed ID: 28699032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of initial prednisolone dose with remission, relapse, and infectious complications in adult-onset minimal change disease.
    Tanabe K; Samejima KI; Fukata F; Kosugi T; Tsushima H; Morimoto K; Okamoto K; Matsui M; Eriguchi M; Maruyama N; Akai Y; Tsuruya K
    Clin Exp Nephrol; 2022 Jan; 26(1):29-35. PubMed ID: 34365595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult minimal-change disease: clinical characteristics, treatment, and outcomes.
    Waldman M; Crew RJ; Valeri A; Busch J; Stokes B; Markowitz G; D'Agati V; Appel G
    Clin J Am Soc Nephrol; 2007 May; 2(3):445-53. PubMed ID: 17699450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
    Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Takeda A; Tsukamoto T; Uchida S; Tsuruya K; Shoji T; Hayashi H; Akai Y; Fukunaga M; Konta T; Nishio S; Goto S; Tamai H; Nagai K; Katafuchi R; Masutani K; Wada T; Nishino T; Shirasaki A; Sobajima H; Nitta K; Yamagata K; Kazama JJ; Hiromura K; Yasuda H; Mizutani M; Akahori T; Naruse T; Hiramatsu T; Morozumi K; Mimura T; Saka Y; Ishimura E; Hasegawa H; Ichikawa D; Shigematsu T; Sato H; Narita I; Isaka Y;
    J Nephrol; 2022 May; 35(4):1135-1144. PubMed ID: 35366214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-Term Steroid Regimen for Adult Steroid-Sensitive Minimal Change Disease.
    Ozeki T; Katsuno T; Hayashi H; Kato S; Yasuda Y; Ando M; Tsuboi N; Hagiwara D; Arima H; Maruyama S
    Am J Nephrol; 2019; 49(1):54-63. PubMed ID: 30557879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study.
    Shinzawa M; Yamamoto R; Nagasawa Y; Oseto S; Mori D; Tomida K; Hayashi T; Izumi M; Fukunaga M; Yamauchi A; Tsubakihara Y; Isaka Y
    Clin J Am Soc Nephrol; 2014 Jun; 9(6):1040-8. PubMed ID: 24721890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome.
    Matsumoto H; Nakao T; Okada T; Nagaoka Y; Takeguchi F; Tomaru R; Iwasawa H
    Intern Med; 2004 Aug; 43(8):668-73. PubMed ID: 15468963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
    Takei T; Itabashi M; Moriyama T; Kojima C; Shiohira S; Shimizu A; Tsuruta Y; Ochi A; Amemiya N; Mochizuki T; Uchida K; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2013 May; 28(5):1225-32. PubMed ID: 23239834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.
    Shinzawa M; Yamamoto R; Nagasawa Y; Oseto S; Mori D; Tomida K; Hayashi T; Izumi M; Fukunaga M; Yamauchi A; Tsubakihara Y; Rakugi H; Isaka Y
    Clin Exp Nephrol; 2013 Dec; 17(6):839-47. PubMed ID: 23512647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome: comparison with prednisolone therapy].
    Hayashi M; Kimura N; Fukatsu A
    Nihon Jinzo Gakkai Shi; 2008; 50(5):581-7. PubMed ID: 18767486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome.
    Nakayama M; Katafuchi R; Yanase T; Ikeda K; Tanaka H; Fujimi S
    Am J Kidney Dis; 2002 Mar; 39(3):503-12. PubMed ID: 11877569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
    Li X; Li H; Chen J; He Q; Lv R; Lin W; Li Q; He X; Qu L; Suya W
    Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.
    Chin HJ; Chae DW; Kim YC; An WS; Ihm C; Jin DC; Kim SG; Kim YL; Kim YS; Kim YG; Koo HS; Lee JE; Lee KW; Oh J; Park JH; Jiang H; Lee H; Lee SK
    J Am Soc Nephrol; 2021 Jan; 32(1):199-210. PubMed ID: 33168602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus as the first-line agent in adult-onset minimal change disease: A randomized controlled study.
    Patil MR; Divyaveer SS; Raychaudhary A; Trivedi M; Mahajan C; Sarkar D; Pandey R
    Saudi J Kidney Dis Transpl; 2019; 30(1):129-137. PubMed ID: 30804274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of biopsy-proven minimal change nephropathy in Chinese adults.
    Szeto CC; Lai FM; Chow KM; Kwan BC; Kwong VW; Leung CB; Li PK
    Am J Kidney Dis; 2015 May; 65(5):710-8. PubMed ID: 25465164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood.
    Hulton SA; Neuhaus TJ; Dillon MJ; Barratt TM
    Pediatr Nephrol; 1994 Aug; 8(4):401-3. PubMed ID: 7947023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.